New Data for Genentech's Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A
Press release content from Business Wire. The AP news staff was not involved in its creation. New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A July 19, 2021 GMT SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul 19, 2021-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the final analysis of the Phase IIIb STASEY study, which confirm the favorable safety profile of Hemlibra ® (emicizumab-kxwh), consistent with the Phase III HAVEN clinical program. In the analysis, no new safety signals ...